Loss of NEIL2 leads to endocrine therapy resistance via dysregulation of the G1-S transition, and miRNA regulation of NEIL2 may mediate the prognosis of hormone-treated breast cancer (Anurag et al., 2018). This evidence concerns the gene NEIL2 and breast carcinoma.